Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07124000) titled 'DESTINY-PANTUMOUR04' on Aug. 13.
Study Type: Observational
Primary Sponsor: AstraZeneca
Condition:
Adenocarcinoma (NOS)
Anal Cancer
Bladder Cancer
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gall Bladder Cancer
Gastrointestinal Stromal Tumour
Head and Neck Cancer
Liver Cancer
Melanoma
Mouth Cancer
Nasopharangeal Cancer
Neuroendocrine, Gastrointestinal Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cell Carcinoma
Salivary Gland Cancer
Sarcoma
Small Cell Lung Cancer
Testicular Cancer
Throat Cancer
Thyroid Cancer
Urethral Cancer
Vaginal Cancer
Vulvar Cancer
Intervention:
Drug: Trastuzumab der...